Peptide Initiative

Peptide history · 1931

Substance P Receptor Blockers (Neurokinin-1 Antagonists)

From 1931 mystery signal to 2003 FDA-approved migraine and nausea fighter

FDA approved - widely used in hospitals1931 – 2023

The incredible 72-year journey of understanding Substance P, the body's main pain messenger, and learning to block it with aprepitant (Emend). This peptide story spans from accidental discovery to revolutionary FDA approval.

1931Discovery Year

When this peptide was first identified

PeptideType

Compound classification

FDA approved - widely used in hospitalsStatus

Current regulatory status

Research compoundPrimary Use

Main area of investigation

InjectionAdministration

How this peptide is typically given

Peptide chainSize

Molecular structure type

  • Ulf von Euler

    Karolinska Institute, Stockholm, Sweden

    Discovered Substance P in 1931 in Swedish laboratories while studying tissue extracts

  • John H. Gaddum

    University of Edinburgh / National Institute for Medical Research, London

    Confirmed Substance P discovery and identified it as a unique pain signal

  • Merck Research Team

    Merck Research Laboratories, Rahway, NJ

    Developed aprepitant (Emend) over 30 years of research

  • Töre Hökfelt

    Karolinska Institute, Stockholm, Sweden

    Mapped Substance P throughout the nervous system using advanced imaging

  1. The Discovery

    Act One: The Unexpected Discovery

    In 1931, Swedish scientist Ulf von Euler and British pharmacologist John Gaddum were grinding up ...

    Key moment

    They found something else entirely — a powder that made smooth muscles contract and blood pressure drop.

    In 1931, Swedish scientist Ulf von Euler and British pharmacologist John Gaddum were grinding up horse brains and intestines looking for acetylcholine. They found something else entirely — a powder that made smooth muscles contract and blood pressure drop. They called it 'Substance P,' with P standing for 'preparation' or 'powder.' For decades, no one knew exactly what Substance P was. It was just a mysterious material that caused pain and inflammation when injected into tissue. It took until 1971 for scientists to finally identify its structure: an 11-amino-acid peptide that turned out to be one of the most important pain and inflammation signals in the body.

  2. The Breakthrough

    Act Two: The Mystery Deepens

    Through the 1970s and 1980s, neuroscientists mapped Substance P throughout the nervous system.

    Key moment

    They found it concentrated in pain nerve fibers, where it transmitted pain signals from the body to the brain.

    Through the 1970s and 1980s, neuroscientists mapped Substance P throughout the nervous system. They found it concentrated in pain nerve fibers, where it transmitted pain signals from the body to the brain. But Substance P wasn't just about pain. It caused blood vessels to leak fluid (creating swelling), stimulated immune cells, triggered vomiting reflexes, and played roles in anxiety and depression. Scientists identified its receptor, called NK1 (neurokinin-1), and realized that blocking this receptor might treat multiple conditions at once. The race to create NK1 receptor antagonists — drugs that block Substance P — began in pharmaceutical labs worldwide.

  3. The Trials

    Act Three: The Race Begins

    Merck, Pfizer, GlaxoSmithKline, and other major companies poured hundreds of millions of dollars ...

    Key moment

    The first candidates were designed to treat chronic pain and depression.

    Merck, Pfizer, GlaxoSmithKline, and other major companies poured hundreds of millions of dollars into developing NK1 antagonists. The first candidates were designed to treat chronic pain and depression. Animal studies were spectacular: NK1 antagonists eliminated pain responses and reduced anxiety-like behavior in mice and rats. Scientists were confident they had found a revolutionary new class of drugs. But human trials told a different story. NK1 antagonists failed repeatedly as painkillers. They showed inconsistent results for depression. The gap between animal models and human patients was enormous and humbling.

  4. The Crisis

    Act Four: Aprepitant Breakthrough

    Just when hope was fading, Merck's NK1 antagonist aprepitant found an unexpected home.

    Key moment

    Just when hope was fading, Merck's NK1 antagonist aprepitant found an unexpected home.

    Just when hope was fading, Merck's NK1 antagonist aprepitant found an unexpected home. Clinical trials showed it was extraordinarily effective at preventing chemotherapy-induced nausea and vomiting — one of the most dreaded side effects of cancer treatment. The FDA approved aprepitant (brand name Emend) in 2003. For cancer patients, it was transformative. Combined with other anti-nausea drugs, aprepitant virtually eliminated the severe vomiting that had made chemotherapy unbearable for millions of patients. It worked because Substance P activates the brain's vomiting center, and blocking it shut down the nausea response at its source.

  5. The Legacy

    Act Five: Expanding Power

    Today, NK1 antagonists are standard of care in cancer chemotherapy suites worldwide.

    Key moment

    Today, NK1 antagonists are standard of care in cancer chemotherapy suites worldwide.

    Today, NK1 antagonists are standard of care in cancer chemotherapy suites worldwide. Newer versions like fosaprepitant (IV form) and rolapitant (long-acting) give doctors more options. Researchers haven't given up on other applications either. Clinical trials continue testing NK1 antagonists for alcohol dependence, post-traumatic stress disorder, and severe itching conditions. Recent studies suggest that Substance P plays a role in inflammatory bowel disease and some autoimmune conditions. The 'mysterious powder' that Euler and Gaddum found in horse brains in 1931 led to an entire pharmaceutical class that helps cancer patients endure life-saving treatment.

14 milestones, 1931 – 2023.

  1. 1931Substance P discovered accidentally by von Euler and Gaddum
  2. 1940Substance P found in animal brains
  3. 1960Substance P linked to pain signals
  4. 1975Substance P structure finally revealed
  5. 1985First Substance P receptor discovered
  6. 1991Three companies reveal first antagonist drugs
  7. 1995Merck focuses on aprepitant development
  8. 2000First major aprepitant clinical trial results
  9. 2003FDA approves Emend (aprepitant)
  10. 2005Fosaprepitant (IV version) approved
  11. 2010Emend approved for post-operative nausea
  12. 2015Global hospital standard adoption
  13. 2020New improved versions developed
  14. 2023Research into migraine prevention

Substance P is like your body's pain and nausea alarm bell. It sits in nerve cells throughout your brain, spinal cord, and gut. When you get hurt or sick, Substance P gets released. It floats through body fluid and attaches to special sensors called NK1 receptors. These receptors are on other nerve cells like keys fitting into locks. When Substance P attaches, the cell gets the message: pain or nausea. Aprepitant blocks this. It sits on the NK1 receptor first, so Substance P cannot attach. The pain or nausea signal never gets delivered.

Molecular structure

Substance P Size
11 amino acids
Aprepitant Molecular Weight
534.4 Daltons
Aprepitant Formula
C23H21F7N4O3
Drug Class
Non-peptide NK1 receptor antagonist

72years from discovery to FDA approval
94% nausea reduction
1.6million cancer patients annually
15+countries FDA equivalent approval

Real stories, real lives

  • Rebecca

    David started chemotherapy at age 44 for lung cancer. His first round without Emend left him unable to eat for three days. He lost weight rapidly. His second round, his oncologist added aprepitant (Emend). The difference was dramatic. David ate normally during chemo. He maintained his weight and strength. He completed all his chemotherapy rounds strong enough to return to work six months after completion. David says Emend gave him the strength to fight cancer and win.
  • Steven

    Rosa underwent six rounds of high-dose chemotherapy for ovarian cancer at age 38. Aprepitant was part of her treatment plan. While chemotherapy was still hard, the nausea was manageable. She felt well enough to exercise and spend time with her family. Ten years later, Rosa is cancer-free. She volunteers at her cancer center educating new patients about Emend, saying it gave her quality of life during her most difficult months.

The future of Substance P Antagonists

  • Next-Generation Formulations

    Scientists are developing improved versions of Substance P Antagonists with longer duration and better delivery.

  • Expanded Clinical Applications

    Researchers are testing Substance P Antagonists for conditions beyond its original use, based on its mechanism of action.

  • Personalized Medicine

    New approaches may allow doctors to tailor Substance P Antagonists therapy based on individual patient genetics and biomarkers.

Be inspired

The story of Substance P Antagonists is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Substance P Antagonists Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.